HER2CLIMB trial results were presented on December 11, 2019 at the 2019 San Antonio Breast Cancer Symposium and published in the New ...
News
- Seattle Genetics Announces Submission of Tucatinib New Drug Application to the US FDA for ...
- Blood testing nears a turning point as the evidence becomes undeniable
At this month's San Antonio Breast Cancer Symposium, Epic presented two research studies of people with metastatic or triple-negative disease, ...
- Puma Biotechnology, Inc. (PBYI) on Focus After Crashing In Today's Session
Puma Biotechnology, Inc. (PBYI) on Focus After Crashing In Today's ... It increased, as 20 investors sold Puma Biotechnology, Inc. shares while 23 ... San Antonio Breast Cancer Symposium – Business Wire” on December 11, 2019, ...
- Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models
"Importantly, the published poster, which can be found on our web site at https://www.moleculin.com/san-antonio-bc-symposium-poster/, shows ...
- Institute to pay $5.5M for not disclosing Chinese grants
In a statement, the institute — an independent biomedical research organization that studies cancer and other diseases— said it did not admit any ...